ProstacycHn protects ischemic reperfused myocardium in the dog by inhibition of neutrophil activation Prostacycln (PGI,) and the stable PGI, analoguo SC39902 (6,s~epoxy&Wfluoro-1 la,15S-dehydroxyprosta-6,13E-dlen-l-ok acid, sodium salt) were studled In anesthetized open-chest dog8 subjected to 90 minutes of left circumflex coronary artery (LCCA) occlusion and 6 hours of reperfusion. PGlp (60 ng/kg/mln, infused into the left atrium) reduced infarct mass by 69% compared to control, but SC39902 (1.5 bg/kg/mln) failed to produce a slgnlficant reduction In Infarct size. Both PGI, and SC39962 reduced mean arterial blood pressure, heart rate, and rate-pressure product to the same extent. Regional myocardial blood flow measured wlth radioiabeiled tracer mlcroepheres dld not demonstrate an increase in regional blood flow to the Ischamk myocardium during the 90 minutes of LCCA occlusion in the PGI, and control treatment groups. Canine neutrophiis were isolated from whole blood and activated with opsonizad zymoaan. PGI, produced a concentration-dependent inhibition of nautrophll activation as measured by superoxide production In vitro, whereas SC39902 failed to effectlveiy inhlbit neutrophii activation. Neutrophll migration into Inflammatory skin lesions was effectively attenuated when dogs were pretreated with PO& (60 ng/kg/mln, Intravenously). Therefore, It is suggested that the cytoprotectiva effect of PGI, during myocardial ischemla and reperfuslon is related to an inhibition of neutrophll migration and the production of cytotoxic activated oxygen species. (AN HEART J 1967; 113: 129.) Prostacyclin (epoprostenol, PGI,) is the major active arachidonic acid metabolite produced by vascular endothelium.1*2 It is the most potent endogenous inhibitor of platelet aggregation yet described,' and is a potent systemic vasodilato~ and coronary artery vasodilator.' Proetacyclin has been demonstrated to be protective in a number of experimental models of myocardial ischemia. 54 Lefer et aLg demonstrated the usefulness of PGI, for the treatment of acute myocardial ischemia. This was based on the ability of PGI, to inhibit platelet aggregation and favorably alter myocardial oxygen supply and demand by increasing coronary artery blood flow and reducing systemic blood pressure, respectively. Melin and BeckerlO demonstrated that PGI, protects in the absence of an increase in collateral blood flow to the ischemic myocardium.
Recent studieF3 have provided substantial evidence to demonstrate that polymorphonuclear leukocyte (neutrophil) infiltration during an evolving myocardial infarct contributes to irreversible myocardial tissue injury. Since prostacyclin inhibits in vitro production of cytotoxic oxygen-free radicals and release of degradative lysosomal enxymes,14-16 we hypothesize that the cytoprotective effect of PGI, in canine regional myocardial ischemia and reperfusion is at least partly due to inhibition of neutrophil activation.
The purpose of this investigation was to determine the effectiveness of PGIz and the chemically stable mono-fluorinated PGI, analogue (SC39992; 6,9cr-epoxy,5S-fluoro-llq 15S-dehydroxy-prosta-6,13E-dien-1-oic acid, sodium salt) for reducing the extent of irreversibly injured myocardial tissue that results after 90 minutes of regional ischemia and 6 hours of reperfusion. We report on the effects of PGI, and SC39962 on canine neutrophil activation by the particulate phagocytic stimulus, opsonixed zymosan, as measured by superoxide anion production in vitro. Additionally, we report that PGI, inhibits neutrophil migration in vivo into inflammatory skin sites at the same dose that reduces myocardial ischemia-reperfusion injury.
METHODS
Details of the methods have been published previously.12v17 Briefly, adult male mongrel dogs (12 to 17 kg) were anesthetized with Dial-urethane (0.6 ml/kg) and ventilated with room air. The proximal left circumflex coronary artery (LCCA) was isolated and instrumented for continuous blood flow measurement with an electromagnetic flow probe. Heart rate, arterial blood pressure, LCCA blood flow, and ECG were continuously recorded. The three experimental groups in the study were: (1) Control (vehicle) (n = 16), 50 mM Tris-HCl, pH 9.4 at 4' C in 0.9% saline; continuous infusion (0.5 ml/mm) into the left atrium beginning 30 minutes before coronary artery occlusion, continuing during the 90 minutes of regional ischemia, and continuing during the first 2 hours of reperfusion. (2) Prostacyclin (n = 14), 50 ng/kg/min in the same vehicle, over the same time course as control. (3) SC39902 (G.D. Searle & Co.) (n = lo), 1.5 &kg/min (same vehicle and time course).
Regional myocardial ischemia was produced by occluding the LCCA for 90 minutes and then reperfusing through a critical stenosis1E for 6 hours. After 6 hours the infarct mass was aasesed with the ex vivo dual perfusion technique previously described,'* in which the LCCA is perfused with 1.5% triphenyltetrazolium chloride in 50 mM potassium phosphate buffer (pH 7.4 at 37' C) and the remainder of the coronaries are perfused with 0.25% Evan's blue dye. The hearts were then cut into five or six 1 cm thick transverse sections. Infarct size was then determined planimetrically.
Regional myocardial blood flow (RMBF). Radioactive microspheres (15 Nrn) (New England Nuclear, North Biller& Mass.) labelled with one of the following five isotopes-Wr, 141Ce, sSSr, lwRu, *SC-were used to assess regional myocardial blood Aow,'~ essentially as detailed previously." The times of microsphere injection were as follows: baseline (before drug or vehicle infusion), 25 minutes after drug or vehicle infusion, 10 minutes after LCCA occlusion, and 30 minutes after LCCA occlusion.
Tissue samples weighing 0.5 to 1.0 gm were dissected from sections of the hearts after staining, from subepicardium, midmyocardium, and subendocardium from the LCCA perfusion region (which was rendered ischemic), and from the normally perfused nonischemic region.
Three sections from each heart were used so that blood flows to each region represent the average of three samples for each experiment.
Histology. A midventricular transmural section of the area of the left ventricle supplied by the LCCA was examined by light microcopy in 21 hearts, seven from each of the three treatment groups (control, PG12, SC39902). Pa&in-embedded tissue blocks were sectioned at 5 thickness and were stained with hematoxylin and eosin. The presence of necrosis was verified and the degree of hemorrhage was assessed by a pathologist (GDA) unaware of the experimental treatment groups.
Neutrophil preparation. Canine neutrophils were isolated from venous blood obtained from untreated dogs and were separated by Hi&opaque (Sigma Chemical Co., St. Louis, MO.) gradient centrifugation followed by red blood cell lysis with a buffered ammonium chloride solution (150 mM [NH,] *C12; 10 mM NaHCO,; 1mM EDTA; pH 7.2). Cell viability was greater than 90% as determined by trypan blue exclusion. Cell preparations consisted of greater than 95% neutrophils.. Superoxide (0,; )production was measured by a modification of the method of Babior et alp as described by Fantone and Kinnes." Neutrophils (5 X 108 cells/ml) were incubated at 37O C in the presence of 0.1 mM ferricytochrome C in Hanks' balanced salt solution (HBSS) with 1 mg/ml glucose. The rate of superoxide production was determined as the superoxide diamutase (SOD) inhibitable (SOD 50 &ml in reference tubes) reduction of ferricytochrome C to ferrocytochrome C with the use of an extinction coefficient of 21.1 mM-' cm-' at 550 mn. After an initial 3-minute incubation at 37O C, Cyto&Iasin B (5 fig/ml san A (Sigma; 10 mg/ml) for 30 minutes at 37' C and then by washing the zymosan twice with sterile normal saline. The OZ was then resuspended in normal saline to 10 mg/ml. Pro&gland& when present, were serially diluted immediately before use in HBSS (4' C) and were added at the' same time as the cells.
Evaluation of neutrophil migration in vivo. Seven dogs were anesthetized with Dial-urethane and (randomized into one of two treatment groups: (1) Prostacyclin, 50 ni/kg/min in vehicle (50 mM Tris HCI buffer (pH 9.4 at 4O C) in 0.9% saline) by intravenous infusion 0.5 ml/min; or (2) Control (vehicle). The chest and back of each dog was carefully shaved and zymosan-activated dog plasma (ZAP) (0.2 ml) was injected intradermally at random sites 30 minutes after the respective intravenous treatment had begun. ZAP was prepared by incubating normal dog plasma with zymosan A (10 mg/ml) for 30 minutes at 37" C and then removing the zymosan by centrifugation.
Biopsies (100 to 300 mg each) were taken at 0,0.5,1.0, and 2.0 hours after ZAP injection. The neutrophil-specific enzyme, myeloperoxidase*l was extracted and measured spectrophotometrically as detailed by Bradley et aL2* The myelo$roxidase content of tissue has been shown to be a good marker of akin neutrophil content.*'tz2
Statistical analyses. Hemodynamic data (heart rate, mean arterial pressure rate-pressure product, LCCA blood flow) and infarct sizes were analyzed with a one-way analysis of variance (ANOVA) at each time point where there were,three groups (control, PGI,, and SC39902). The &ups of data that were found to be significantly different from the ANOVA were analyzed further with Dunnett's test for multiple comparisons to control.23 p values less than 0.05 were considered significant. Regional myocardial blood flows (RMBFs) were analyzed with unpaired Student's t tests for each comparison between the two treatment groups. Paired Student's t tests were used to test for differences with time in the RMBF studies?' A Bonferroni a-error protection was used if any of these differences were found to be significant. In vitro superoxide production was analyzed by unpaired Student's t test for each concentration of PGI, or SC39902 compared to the superoxide production in the absence of either PGI, or SC39902. Myeloperoxidase content of tissue samples were compared by Student's t test.
RESULTS
Thirty-four dogs were assigned randomly to one of the three treatment groups (control, PG12, or SC39902) for initial assessment of drug effect on resulting myocardial infarct size. Three dogs, one from each of the three treatment groups, were eliminated due to ventricular fibrillation during reperfusion which was not converted with fewer than four DC countershocks. Fourteen more dogs were randomized into one of two treatment groups (control or PGI,) for assessment of treatment effects on changes in RMBF. Of these 14 dogs, three control dogs and one PGI,-treated dog were eliminated from the study due to ventricular fibrillation.
Two more dogs (one control, one PGIJ were eliminated from the study due to technical problems with microsphere injection and reference blood sample withdrawals.
Hemodynamlc effects of PGll and SC3WO2. The doses of PGI, (50 ng/kg/min) and SC39902 (1.5 &kg/min) were chosen on the basis of their ability to produce a similar decrease in blood pressure. Pro&a&in infusion resulted in a 23% reduction (-27 mm Hg) in mean arterial blood pressure (MAP) ( Table I) 115 + 5 to 88 f 5 mm Hg (n = 14). Similarly, infusion of SC39902 resulted in a reduction in MAP from 119 + 6 to 101 rt 5 mm Hg (n = 10). Occlusion of the LCCA typically results in a decline in MAP, as demonstratd in Table I comparing control before occlusion (119 + 4 mm Hg) to control at 30 minutes of regional myocardial ischemia (93 f 4 mm Hg). MAP was comparable after LCCA occlusion among all three treatment groups throughout the 6-hour reperfusion period.
Baseline heart rates (HR) ( Table I) were slower in the PGIz-treated group (p < 0.06); however, after 30 minutes of PGI, or SC39902 infusion, both PGI, and SC39902 groups had significantly slower heart rates compared to control (both p < 0.05). Heart rates were comparable among groups during the 90-minute ischemic period and throughout the 6-hour reperfusion period.
Rate-pressure product (RPP) (systolic blood pressure x heart rate/lOOO) is used as an index of myocardial oxygen consumption.25 RPP was monitored throughout the experiments to determine whether changes in oxygen demand due tc treatment could be responsible for any protective effect on the resulting myocardial infarct size. Baseline mean values for RPP did not difk'er among the three treatment groups (Table I) However, after 30 minutes of infusion of PGI, or SC39902, rate-pressure product was significantly reduced in both PGI, and SC39902 treatment groups compared January 19%' Ametlcan Heart Journal to control @ < 0.01). Upon LCCA occlusion, this index was similar among groups and remained so throughout the g-hour reperfusion period. Mean LCCA blood flows were comparable before treatment (Fig. 1) . After 30 minutes of infusion of PGI, or SC39902, LCCA coronary blood flows were similar when compared to the vehicle control group (control = 27 & 3 ml/min, n = 16; PGI, = 19 + 2 ml/min, n = 14; SC39902 = 22 + 4 ml/min, n = 10; PGI, both p > 0.05 compared to control). After 90 minutes of complete LCCA occlusion, blood flow was resumed slowly over 15 minutes. All mean LCCA blood flows were comparable among groups at every time point observed subsequent to reperfusion.
Effects of PGlz and SC39902 on infarct size. The effects of PGI, and SC39902 on resulting myocardial injury due to ischemia and reperfusion are depicted in Fig. 2 Regional myocardial blood flows were determined at four time points during the experiments (Fig. 3) . The purpose of measuring RMBF is to determine whether the protective effect of PGI, on the evolving mass of myocardial infarct is due to alteration of regional blood flow distribution.
LCCA occlusion resulted in a significant decline in myocardial blood flow in all three myocardial regions (subepicardial, midmyocardial, and subendocardial) and to a similar extent in both control and the PGI, treatment groups. Endocardial blood flow was reduced by 91% and 93 % in control and pro&a&in treated groups, respectively; midmyocardial flow declined by 84% (control) and 91% (PGI,); and epicardial flows declined by 67 % (control) and 85% (PGIJ. Blood flows in each of the three regions were not increased during LCCA occlusion in the ischemic perfusion bed when early (10 minutes after occlusion) and late occlusion (30 minutes after occlusion) flows were compared (paired t test). Therefore, there was no significant increase in collateral flow that could account for the protective effect of PGI, on the evolving infarct mass. EndocardiaUepicardial blood flow ratios were calculated to determine if the blood was being redistributed within the myocardium. Endocardial/epicardial flow ratios remained unchanged with treatment (control pretreatment 1.38 * 0.07 .ml/min/gm, after vehicle 1.38 + 0.08 ml/min/gm; PGI, pretreatment 1.17 + 0.03 ml/min/ gm, after PGI, 1.08 k 0.09 ml/min/gm) in the region of the myocardium perfused by the LCCA. The endocardial/epicardial ratios during occlusion within the ischemic area were 0.4 + 0.11 for the PGI, group and 0.15 t-0.40 for the control group 0, > 0.05). This again confkns that the protective effect of PGI, on infarct size is independent of blood flow redistribution.
Blood flows in the area of the heart not rendered ischemic are depicted on the right side of Fig. 3 . As is evident from the figure, there were no significant differences in blood flows in this region with time (paired t test) or between groups (control, PGIJ at any time tested (unpaired t test). EndocardiaVepicardial flow ratios in the nonischemic regions were similar to endocardial/epicardial ratios obtained in the region perfused by the LCCA. Histology. Representative transmural sections from each of 21 hearts were used to assess relative degree of ischemic injury by light microscopy. Tissue samples were prepared for histologic examination such that regions from the central infarct area, the border region between normal tissue and neerotic tissue, and the normal tissue were analyzed. No &nificant differences were observed among the three treatment groups (control, PGI,, SC39%2) with respect to the appearance of the-necrotic tissue in the central infarct area. No differences among treatment groups were discernible with respect to the extent of hemorrhage in the infarct area or border regions. Gross inspection of histologic sections revealed no dis~rnible differences in relative neutrophii content in infarcted tkisue or border regions. Frequency or uentricular flbrWt#on. The development of spontaneous ventricuiar fibrillation (YF) was monitored in this study to determine whether PGIe or SC39902 may a&t the frequency of VP. Previous reporta suggest that PGI, and ,PGI, analogue8may be either antiarrhythmic or arrhythmogenic, depending on the dose of drug ,J.NKxL~,~' The overall incidence of VF was 7 of 46 dogs in the study with control frequency of 4 of 19, for PGI, it was 2 of 18 dogs, and for SC39902 it wan 1 of 11 dogs (chi s&are = 1.166, p > 0.05). Therefore was no dif.@r-ence in the relative frequency of observed in this study.
In vitro ~upewxtd0 production by oar~lni niuw.
Ctiine ~eutzoph& 'were stimuhs&ed with 02 and superoxide Oa-generation was ma&ored qe@ro-photometriklly (at 550 mn) by the superoxide dismutase inhibitable reduction .of ferriqW&rome C. Fig. 4 dernonstrafea that proetaoyohn prodti a concentration-dependent inhibition of neutrophii activation. The rate of superoxide production in the absence of PGI, or SC39902 ~88 15. nmolea 0,;/5 x lo6 cells/l0 minutes. PGI, at a concentration of lo-'M inhibited 0,: production by 27 % compared to control (no PG). At a PGI, concentration of lo-'M, superoxide production was inhibited by 55% compared to control. In contrast, SC39902 did not ahow a concentration-dependent inhibition of superoxide production. Moreover, SC39902 at a concentration of 10-W was the only concentration that was found to be significanfly different from control. At this concentration, SC39902 inhibition wa+3 only 11% compared to control.
Neutrophil migration into dermal inflammatory leaions. Fig. 5 shows that prostacyclin at 50 ng/kg/min effectively inhibits neutrophil migration into skin lesions induced by activated complement fragments (primarily C5a de&g). The myeloperoxidase content at the time of zymosan-activated plasma (ZAP) injection was 0.41 u 0.08 U/gm in the vehicle treated group and 0.M -t 0.24 U/gm in the PGI, treated group (p > 0.05). The myeloperoxidase content of skin lesions W8S ly less at 0.5, 1.0 and 2.0 hours after ZAP injection (all p < 0.01 compared to control). Furthermore, neutrophilic infiltration in the PGIz treated dogs was only 36.3% of the control value at the 2 hour time point (14.68 +: 3.01 Ufgm vs 5.33 rt 0.65 Wm). DISCUSSION A number of investigators have attempted to define the relevant mechanism for the myocardial protection by prostacyclin in the setting of experimental myocardial ischemia.6-10~28* 2g The reduction of arterial blood pressure by PGIz would at least theoretically reduce myocardial ischemia by reducing afterload and thus myocardial oxygen demand.30*31 In the present study; myocardial oxygen consumption as estimated by the rate-pressure productz5 was reduced to the same extent by PG12 and SC39902 (Table I) . Prostacyclin resulted in a 59% reduction in infarct size with respect to the area at risk compared to controls, whereas SC39902 failed to reduce infarct size (Fig. 2) . The relevant mechanism of protection by PGI, is therefore not due to a reduction in myocardial oxygen demand.
Jugdutt et al.6 demonstrated that PG4 by virtue of its vasodilatory properties, increased collateral blood flow to the ischemic myocardium in closed-chest conscious dogs subjected to permanent coronary artery occlusion. Indeed, in the aforementioned study, protection of the ischemic myocardium after permanent coronary artery occlusion is probably dependent upon the ability of PG12 to increase collateral blood flow, since PGE, and PG12 reduced infarct size while PGE, did not. Prostaglandins E, and I2 increased collateral blood flow in that study but PGE2 did not, while all three prostaglandins produced a similar reduction in blood pressure. In another study, Melin and BeckerlO demonstrated that even in the absence of increased collateral blood flow to the ischemic myocardium, PGI, treatment resulted in a reduction in myocardial necrosis. We report that PGI, reduced infarct mass without increasing collateral blood flow to the ischemic myocardium during 90 minutes of regional ischemia. LCCA blood flow during reperfusion was similar among the three treatment groups (control, PG12, X39902; Fig.  l) , suggesting that the mechanism of protection was independent of changes in blood flow to the previously ischemic myocardium and was not related to the "noreflow" phenomenon. 32 We hereby offer an alternative explanation for the cytoprotective effect of PG12 in ischemic myocardium in vivo. Prostacyclin can inhibit human neutrophil stimulation by formylmethionyl-leucyl-phenylalanine (fMet-Leu-Phe) and zymosan activated serum (complement activation products) as determined by superoxide production and lysosomal enzyme release in vitro.L'L6 In addition, prostaglandms of the E series inhibit neutrophi1 chemotaxis, superoxide production, and degranulation in a variety of species, presumably through an increase in neutrophil intracellular concentration of cyclic adenosine monophosphate (AMP). 16 We report in this study that PG12 can effectively inhibit canine neutrophil activation in vitro as measured by superoxide-specific reduction of ferricytochrome C. The PGI, analogue SC39902 manifests hemodynamic effects similar to those of PGI, in vivo (i.e., reduces blood pressure) and also inhibits platelet aggregation in vitro (unpublished observations). A recent report33 demonstrated that SC39902 is an effective inhibitor of platelet activation in vivo as measured by the ability to prevent adenosine diphosphate (ADP)-induced thrombocytopenia in rats. Despite these similarities to PG12, the analogue SC39902 failed to produce effective inhibition of canine neutrophil activation in vitro when stimulated with OZ. Furthermore, SC39902 does not protect the ischemic-reperfused myocardium with respect to ultimate infarct size. We propose, therefore, that the relevant mechanism for PG12 protection in our experimental model is via the inhibition of neutrophil activation.
The concentration of PG12 that produces 50% inhibition of neutrophil O,-production is very similar to the 30 PM of PGI, for 50% inhibition reported by Fantone and Kinnes.14 The concentrations of PGI, achieved in vivo with an infusion rate of 50 ng/kg/min would be expected to approach the concentration range of 10e7 in vivo. Furthermore, inhibition of neutrophil migration in vivo by PGI, (50 ng/kg/min) was demonstrated and is likely to be the relevant mechanism of protection of the ischemic reperfused myocardium.
The proinflammatory role of the neutrophil during myocardial ischemia and reperfusion injury has been demonstrated." Hill and Ward34 in 1971 demonstrated that complement is activated via the alternative pathway during myocardial ischemia. Maroko et a1. 35 depleted dogs of complement component 3 (C3) with cobra venom factor. Complement depletion resulted in reduced tissue damage and reduced neutrophil infiltration into the ischemic myocardium. Pinckard et a1.36 extended these observations to the baboon, and demonstrated complement localization within the ischemic myocardium by direct immunofluorescence methods. Neutrophils, when activated by complement fragments, produce oxygen-derived free radicals and release degradative lysosomal enzymes, both of which are capable of mediating tissue destruction.
Using another approach, Romson et a1.12 demonstrated a 44% reduction in the mass of myocardial infarct that evolved when dogs were made neutropenic before the induction of regional myocardial &hernia. In a related study, Romson et al." demonstrated that the protective effect of ibuprofen (a nonsteroidal antiinIlammatory agent) upon the ischemic/reperfused myocardium was correlated with the ability of the drug to inhibit the infiltration of neutrophils into the ischemic myocardium. Kuehl et a1.37 demonstrated that PGI, inhibits neutrophil lipoxygenase activity. Neutrophil lipoxygenase products provide an important proinflammatory amplification signal. Leukotriene B,, produced by neutrophils, is a potent chemoattractant for neutrophils, macrophages, and blood monocytes. Inhibition of lipoxygenase by PGIz would therefore result in a reduction in phagocytic cell infiltration and thus reduce cellular necrosis.
In summary, we report the effectiveness of PGI, for reducing myocardial infarct mass in the dog with temporary regional myocardial ischemia and reperfusion. The PGI, analogue SC39902 produced a similar reduction in arterial blood pressure and heart rate but failed to reduce infarct mass. In vitro canine neutrophil activation was inhibited in a concentration-dependent manner by PGII, whereas SC39902 failed to effectively inhibit neutrophil activation over the same concentration range. The data on neutrophil migration into inflammatory skin lesions demonstrate that neutrophil function is affected in vivo at the same dose of PGI, that reduces myocardial ischemic reperfusion injury. These data suggest that the cytoprotective effect of PGI, in this experimental model of myocardial infarction is due to inhibition of neutrophil activation.
The studies described in this report may have relevance with respect to the clinical management of patients who are evolving an acute myocardial infarction and who become candidates for thrombolytic therapy with streptokinase or perhaps tissue plasminogen activator. There are sufficient data to suggest that PGI, is capable of preventing platelet aggregation2 and that the prostanoid may be of value as an adjunct to thrombolytic therapy, whereby it may serve to prevent reocclusion of the successfully recanalized coronary artery?* The data presented in this report might give added importance for the concomitant use of PGI, along with thrombolytic therapy as an approach for the prevention of that component of myocardial injury associated with reperfusion of the ischemic heart. Furthermore, our data with respect to the cytoprotective effect of PGI*, while in agreement with that of previous investigators,5-'0 provide an explanation for the mechanism by which PGIz elicits its beneficial action through an inhibition of neutrophil function.
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